SciELO - Scientific Electronic Library Online

vol.42 issue6Hepatitis B and C virus markers among patients with hepatosplenic mansonic schistosomiasisEvaluation of penicillin therapy in patients with leptospirosis and acute renal failure author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Revista do Instituto de Medicina Tropical de São Paulo

On-line version ISSN 1678-9946


OLIVEIRA-NETO, Manoel Paes de et al. Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime ®) in Rio de Janeiro, Brazil. Rev. Inst. Med. trop. S. Paulo [online]. 2000, vol.42, n.6, pp.321-325. ISSN 1678-9946.

Response to treatment with antimonial drugs varies considerably depending on the parasite strain involved, immune status of the patient and clinical form of the disease. Therapeutic regimens with this first line drug have been frequently modified both, in dose and duration of therapy. A regimen of 20 mg/kg/day of pentavalent antimony (Sb5+) during four weeks without an upper limit on the daily dose is currently recommended for mucosal disease ("espundia"). Side-effects with this dose are more marked in elderly patients, more commonly affected by this form of leishmaniasis. According to our experience, leishmaniasis in Rio de Janeiro responds well to antimony and, in cutaneous disease, high cure rates are obtained with 5 mg/kg/day of Sb5+ during 30 to 45-days. In this study a high rate of cure (91.4%) employing this dose was achieved in 36 patients with mild disease in this same geographic region. Side-effects were reduced and no antimony refractoriness was noted with subsequent use of larger dose in patients that failed to respond to initial schedule.

Keywords : Mucosal leishmaniasis; Leishmania (Viannia) braziliensis; Antimony; Therapy.

        · abstract in Portuguese     · text in English     · English ( pdf epdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License